Industries > Pharma > Top 25 Dermatological Drugs Manufacturers 2019

Top 25 Dermatological Drugs Manufacturers 2019

Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies

PUBLISHED: 15 April 2019
PAGES: 176
PRODUCT CODE: PHA0380

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

Dermatological drugs market has been growing over the last decade. A combination of significant new market launches, and corporate activities has changed the outlook of the pharmaceutical industry towards this market. The dermatological drugs market in 2018 was reported to be US$ 26.23bn. Visiongain’s analysis of the market shows Humira, Stelara, Enbrel, Remicade, Otezla and Cosentyx among the top dermatological drugs driving the market at present.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 176-page report you will receive 108 tables and 71 figures– all unavailable elsewhere.

The 176-page report provides clear detailed insight into the top 25 dermatological drugs manufacturers. Discover the key drivers and challenges affecting the market.

Report Scope

• Assessment of the leading companies in the global dermatological drugs market. The list below shows some of the companies that are discussed in the report:
• Abbvie Inc.
• Allergan plc
• Almirall S.A.
• Amgen
• Astellas
• Bayer
• Concert Pharmaceuticals
• Eli Lilly and Company
• Galderma
• GlaxoSmithkline plc (GSK)
• Johnson & Johnson (J&J)
• Leo Pharma A/S
• Lupin Ltd
• Mayne Pharma
• Other companies

• For each company, the report provides information and discussion on:
• Total revenue forecast to 2028
• Dermatology segment revenue forecast to 2028
• The leading dermatology drugs revenue forecast to 2028
• Drugs portfolio
• Recent developments

• The report provides revenue forecast to 2028 for the following dermatological drugs:
• Epiduo
• Differin
• Stelara
• Remicade
• Humira
• Valtrex
• Lamisil
• Bactroban
• Dermovate
• Zyvox
• Protopic
• Solodyn
• Ziana
• Taltz
• Cosentyx
• Aczone
• Cubicin
• Elocon
• Absorica /Epirus
• Enbrel
• Doryx
• Canesten
• Bepanthen/Bepanthol

• Key questions answered by this report:
• How is the Dermatological Drugs Manufacturers market evolving?
• What is driving and restraining the Dermatological Drugs Manufacturers market?
• What will be the main driver for the overall market to 2028?
• Will leading Dermatological Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?

Visiongain’s study is intended for anyone requiring commercial analyses for the Top 25 Dermatological Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 25 Dermatological Drugs Manufacturers 2019: Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Top 25 Dermatological Drugs Manufacturers 2019


Download sample pages

Complete the form below to download your free sample pages for Top 25 Dermatological Drugs Manufacturers 2019


Latest Pharma news

“Biological Drug API Manufacturing market set to grow to $11bn by 2025” says Visiongain report

Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes.

07 November 2019

READ

“global radiation oncology market is anticipated to surpass USD 6.5 billion by 2020”, says Visiongain

Growing aging population, urbanization, and growing wealth in low- and middle-income countries such as China and India are anticipated to boost the APAC radiation oncology market.

07 November 2019

READ

“Global Rabies Diagnostics Market is anticipated to surpass USD 1.8 billion by 2020”, says Visiongain

Several international healthcare organizations are working with healthcare organizations to develop and market new detection assays to drive efforts aimed at fighting the disease.

07 November 2019

READ

“Global spinal muscular atrophy (SMA) market is anticipated is to surpass USD 950 Million by 2020”, says Visiongain

Increasing awareness of SMA and increasing numbers of programs to expand treatment options for rare diseases are key factors that are boosting the market growth.

07 November 2019

READ

Categories

Category